Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 96 results found since Jan 2013.
Reflections on the Future of Medicine
Recently, I traveled through China. I climbed mountains, hiked through forests, crossed deep valleys. I visited cities of every size. I floated across lakes and traveled beautiful shorelines churning with life. As a man of a certain age, I began to compare the permanence of the timeless landscape with the evanescence of my own existence. Yet, as a scientist, I knew these reflections were flawed.
Scientists are trained to think in terms of aeons, millenia, and lifetimes. Consider the paradox. Is it the solid mountain or fragile the forest that is permanent? Is it the massive shoreline cliffs or the teeming shore life that...
Source: Science - The Huffington Post - January 9, 2017 Category: Science Source Type: news
Morning Rounds: Arthritis, immunotherapy and strokes
This week the CDC published a "Vital Signs" report highlighting the growing incidence of arthritis, estimated to affect about 54 million adults in the country. Also: CBS News chief medical correspondent Dr. Jon LaPook previews his "Sunday Morning" report on immunotherapy, which harnesses the body's own immune system to find and destroy cancer cells; and CBS News contributor Dr. Tara Narula reports on an innovation in stroke treatment.
Source: Health News: CBSNews.com - March 11, 2017 Category: Consumer Health News Source Type: news
The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets
AbstractCerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid β-protein (Aβ) in the leptomeningeal and cortical blood vessels, which is an age-dependent risk factor for intracerebral hemorrhage (ICH), ischemic stroke and contributes to cerebrovascular dysfunction leading to cognitive impairment. However clinical prevention and treatment of the disease is ver y difficult because of its occult onset and severity of the symptoms. In recent years, many anti-amyloid β immunotherapies have not demonstrated clinical efficacy in subjects with Alzheimer’s disease (AD), and the failure may be due to th...
Source: Translational Neurodegeneration - August 17, 2017 Category: Neurology Source Type: research
Tissue-type plasminogen activator regulates macrophage activation and innate immunity
Tissue-type plasminogen activator (tPA) is the major intravascular activator of fibrinolysis and a ligand for receptors involved in cell signaling. In cultured macrophages, tPA inhibits the response to lipopolysaccharide (LPS) by a pathway that apparently requires low-density lipoprotein receptor-related protein-1 (LRP1). Herein, we show that the mechanism by which tPA neutralizes LPS involves rapid reversal of IBα phosphorylation. tPA independently induced transient IBα phosphorylation and extracellular signal-regulated kinase 1/2 (ERK1/2) activation in macrophages; however, these events did not trigger inflam...
Source: Blood - September 14, 2017 Category: Hematology Authors: Mantuano, E., Azmoon, P., Brifault, C., Banki, M. A., Gilder, A. S., Campana, W. M., Gonias, S. L. Tags: Immunobiology and Immunotherapy, Phagocytes, Granulocytes, and Myelopoiesis, Thrombosis and Hemostasis Source Type: research
UCLA helps many to live long and prosper
In Westwood, more than 100 faculty experts from 25 departments have embarked on anall-encompassing push to cut the health and economic impacts of depression in half by the year 2050. The mammoth undertaking will rely on platforms developed by the new Institute for Precision Health, which will harness the power of big data and genomics to move toward individually tailored treatments and health-promotion strategies.On the same 419 acres of land, researchers across the spectrum, from the laboratory bench to the patient bedside, are ushering in a potentially game-changing approach to turning the body ’s immune defenses again...
Source: UCLA Newsroom: Health Sciences - November 9, 2017 Category: Universities & Medical Training Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study
Conclusions. The results of this real-life study show that in unselected patients with R/R CLL the clinical activity of ibrutinib was comparable to that reported in CTs. However, a third of patients discontinued ibrutinib within 24 months from the start of treatment. An earlier introduction of ibrutinib in the treatment approach of R/R patients, a careful surveillance and management of toxicities will optimise the clinical benefits of ibrutinib in CLL patients treated in the clinical practice.DisclosuresMauro: Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Membership on...
Source: Blood - November 21, 2018 Category: Hematology Authors: Mauro, F. R., Soddu, S., Frustaci, A. M., Orsucci, L., Motta, M., Scarfo, L., Zinzani, P. L., Falzetti, F., Farina, L., Marasca, R., Cortelezzi, A., Carlo-Stella, C., Molica, S., Coscia, M., Zaja, F., Laurenti, L., de Fabritiis, P., Gaidano, G., Gobbi, M. Tags: 642. CLL: Therapy, excluding Transplantation: Poster II Source Type: research
Study links psoriasis treatment and improvement in heart artery disease
(NIH/National Heart, Lung and Blood Institute) Researchers have found that treating psoriasis, a chronic inflammatory skin disease, with biologic drugs that target immune system activity can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke. The findings highlight how immunotherapies that treat inflammatory conditions might play a role in the reduction of cardiovascular disease risks.
Source: EurekAlert! - Medicine and Health - February 5, 2019 Category: International Medicine & Public Health Source Type: news
Recurrent stroke due to antiphospholipid syndrome remitted by immunotherapy, not by anticoagulation therapy: A case report and literature review
Jin-Mo Park, Kyung Yoon EahAnnals of Indian Academy of Neurology 2019 22(2):250-252
Source: Annals of Indian Academy of Neurology - April 8, 2019 Category: Neurology Authors: Jin-Mo Park Kyung Yoon Eah Source Type: research
6-Bromoindirubin-3 ′-Oxime (6BIO) Suppresses the mTOR Pathway, Promotes Autophagy, and Exerts Anti-aging Effects in Rodent Liver
In this study, we aimed to investigate the anti-aging effect, and molecular mechanism, of the novel anti-aging drug 6BIO on naturally aged mouse liver. Rapamycin, a well-known promising anti-aging drug that delays aging through mTOR-dependent autophagy (Zhou and Ye, 2018), was used as the positive control in the study. To our knowledge, this is the first study to demonstrate the effects of 6BIO treatment in models of natural aging.
Our results indicated that 6BIO ameliorates the decline of liver function with age, including lipid metabolism disorder, and attenuates hepatocyte senescence in aged mice, as revealed by altera...
Source: Frontiers in Pharmacology - April 9, 2019 Category: Drugs & Pharmacology Source Type: research
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
Recurrent Stroke in Giant Cell Arteritis Despite Immunotherapy
Conclusions:
This case highlights several important features of strokes in GCA: the predilection for the dural entry point of cerebral blood vessels, the progression of disease despite steroids, and the need to quickly escalate treatment in these cases. As seen in our patient, however, this disease carries high morbidity and mortality and patients often have poor outcomes despite aggressive immunosuppression.
Source: The Neurologist - June 28, 2019 Category: Neurology Tags: Case Report/Case Series Source Type: research
The Director of the NIH Lays Out His Vision of the Future of Medical Science
Our world has never witnessed a time of greater promise for improving human health. Many of today’s health advances have stemmed from a long arc of discovery that begins with strong, steady support for basic science. In large part because of fundamental research funded by the National Institutes of Health (NIH), which traces its roots to 1887, Americans are living longer, healthier lives. Life expectancy for a baby born in the U.S. has risen from 47 years in 1900 to more than 78 years today. Among the advances that have helped to make this possible are a 70% decline in the U.S. death rate from cardiovascular disease ...
Source: TIME: Science - October 24, 2019 Category: Science Authors: Dr. Francis S. Collins Tags: Uncategorized Healthcare medicine Source Type: news
12 Innovations That Will Change Health Care and Medicine in the 2020s
Pocket-size ultrasound devices that cost 50 times less than the machines in hospitals (and connect to your phone). Virtual reality that speeds healing in rehab. Artificial intelligence that’s better than medical experts at spotting lung tumors. These are just some of the innovations now transforming medicine at a remarkable pace.
No one can predict the future, but it can at least be glimpsed in the dozen inventions and concepts below. Like the people behind them, they stand at the vanguard of health care. Neither exhaustive nor exclusive, the list is, rather, representative of the recasting of public health and medic...
Source: TIME: Health - October 25, 2019 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized HealthSummit19 technology Source Type: news
U.S. Cancer Death Rates Continue to Drop, But Progress Is Stalling for Some Cancers
Over the last few decades, the death rate from cancer dropped by 29% in the U.S., according to the latest data from the American Cancer Society (ACS). That, the ACS’s new study estimates, saved 2.9 million lives from 1991 to 2017, largely owing to declines in mortality from the four leading cancer types: lung, breast, prostate and colon.
From 2016 to 2017—the latest year for which data are available—the overall cancer death rate declined by 2.2%, the largest single-year reduction ever recorded. These new figures were reported in a study published in CA: A Cancer Journal for Clinicians.
The declines are a...
Source: TIME: Health - January 8, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer Source Type: news
